High-mobility group box 1 inhibition alleviates lupus-like disease in BXSB mice

Scandinavian Journal of Immunology

Volumn 79, Issue 5, 2014, Pages 333-337

  Zhang, C ^a   Li, C ^a   Jia, S ^a   Yao, P ^a   Yang, Q ^b   Zhang, Y ^b  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; CREATININE; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP BOX 1 PROTEIN MONOCLONAL ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GLOMERULONEPHRITIS; HISTOPATHOLOGY; IMMUNE COMPLEX DEPOSITION; LUPUS LIKE SYNDROME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SPLENOMEGALY; URINARY EXCRETION;

ALBUMINS; ANIMALS; ANTIBODIES, BLOCKING; CASPASE 1; CREATININE; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA; HMGB1 PROTEIN; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED STRAINS; MOLECULAR TARGETED THERAPY; SPLEEN;

EID: 84898905012     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12165     Document Type: Article

References (26)

1. Erlandsson Harris H, Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004;34: 1503-12.
2. Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 2010;51:119-26.
3. Vitali R, Stronati L, Negroni A et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol 2011;106:2029-40.
4. O'Connor KA, Hansen MK, Rachal Pugh C et al. Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine 2003;24:254-65.
5. Ostberg T, Kawane K, Nagata S et al. Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum 2010;62:2963-72.
6. Hamada T, Torikai M, Kuwazuru A et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 2008;58:2675-85.
7. Urbonaviciute V, Fürnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008;205:3007-18.
8. Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C. Pathogenic anti-dsDNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-dsDNA antibody-induced renal injury. Immunol Lett 2008;121:61-73.
9. Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010;37:766-75.
10. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
11. Qin S, Wang H, Yuan R et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006;203:1637-42.
12. Sadanaga A, Nakashima H, Akahoshi M et al. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum 2007;56:1618-28.
13. Moser K, Kalies K, Szyska M, Humrich JY, Amann K, Manz RA. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice. Arthritis Rheum 2012;64:1237-46.
14. Yan W, Chang Y, Liang X et al. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 2012;55:1863-75.
15. Kahlenberg JM, Yalavarthi S, Zhao W et al. An essential role for caspase-1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheum 2014;66:152-62.
16. Merrill JT, Ginzler EM, Wallace DJ et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:3364-73.
17. Baumann I, Kolowos W, Voll RE et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:191-201.
18. Pisetsky DS. HMGB1: a dangerous player in lupus pathogenesis. J Rheumatol 2010;37:689-91.
19. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96.
20. Avalos AM, Kiefer K, Tian J et al. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity 2010;43:103-10.
21. Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol 2009;19:283-92.
22. Eljaafari A, Tartelin ML, Aissaoui H et al. Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis. Arthritis Rheum 2012;64:2147-57.
23. Shin MS, Kang Y, Lee N et al. U1-small nuclear ribonucleoprotein activates the NLRP3 inflammasome in human monocytes. J Immunol 2012;188:4769-75.
24. Shin MS, Kang Y, Lee N et al. Self double-stranded (ds)DNA induces IL-1β production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J Immunol 2013;190:1407-15.
25. Zhao J, Wang H, Dai C et al. p2x7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/Caspase 1 pathway. Arthritis Rheum 2013;65:3176-85.
26. Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 2013;190:1217-26.